drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Intravenous CD20×CD3 bispecific antibody that binds CD20 on lymphoma cells and CD3 on T cells, redirecting and activating T cells to kill B cells.
nci_thesaurus_concept_id
C148486
nci_thesaurus_preferred_term
Glofitamab
nci_thesaurus_definition
A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.
drug_mesh_term
glofitamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Glofitamab is a bispecific monoclonal antibody that simultaneously binds CD20 on B‑cell lymphoma cells and CD3 on T cells, crosslinking the two to redirect and activate T cells. This induces T‑cell activation and cytotoxicity against CD20‑expressing B cells, leading to targeted tumor cell lysis.
drug_name
Glofitamab
nct_id_drug_ref
NCT06054776